Shuttle Pharmaceuticals News

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 24 04:42

Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Apr 6 05:10

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Fourth Quarter 2023 Corporate Update

Mar 22 21:02

Shuttle Pharmaceuticals | 424B3: Prospectus

Mar 22 18:11

Shuttle Pharmaceuticals | 10-K: Annual report

Mar 22 05:32

Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Senanayake Chris

Mar 15 05:06

Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Vander Hoek Michael

Mar 9 07:21

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmicals Receives Notice of Nasdaq's Failure to Satisfy Continued Listing Rules and CEO Anatoly Dritschilo to Attend Emerging Growth Conference on March 6, 2024

Mar 5 22:02

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13 21:04

Shuttle Pharmaceuticals | 8-K: Asset Purchase Agreement

Feb 6 05:28

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8 13:00

Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Brown Milton

Jan 2 13:00

Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Jacobs Bette

Dec 21, 2023 10:51

Shuttle Pharmaceuticals | 8-K: Poll Results of 2023 Stockholders Meeting

Dec 20, 2023 06:10

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Dec 11, 2023 22:00

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 30, 2023 22:00

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Nov 14, 2023 22:12

Shuttle Pharmaceuticals: Q3 2023 Earnings Report

Nov 14, 2023 05:21

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 31, 2023 05:14

Shuttle Pharmaceuticals | ARS: Annual Report to Security Holders

Oct 21, 2023 04:15